Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Colfax Plans To Split To Form Separate Medtech And Fabtech Companies

Executive Summary

The yet-to-be-named medtech company will focus on orthopedic implants and bracing and recovery devices.

You may also be interested in...



Orthopedic Roundup Q4: S&N, Stryker, J&J, Zimmer Biomet See Pandemic-Related Sales Impact

The resurgence of the pandemic during the fourth quarter of 2020 led to slowdown in elective procedures, negatively impacting sales of the four big ortho players.

Market Brief: Extremity Replacement Market Expected To Reach $2Bn By 2024

Despite COVID-19, the market for extremity replacement implants looks healthy in the medium-term, with strong growth predicted as elective surgeries return.

Smith & Nephew Pays $240M For Integra’s Extremities Business

Integra is divesting its underperforming extremity orthopedics product portfolio to focus on its neurosurgery, surgical instrument and regenerative medicine businesses.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT143609

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel